



## NOV 3 0 2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Susan A. GREENFIELD et al.

Attn: BOX CPA

Docket No. 01727/N.80406 US/JCI/cl

Serial No. 09/155,076

Group Art Unit 1647

Filed October 23, 1998

Examiner S. Turner

PEPTIDE FROM SOLUBLE FORM OF ACETYLCHOLINESTERASE, ACTIVE AS A CALCIUM CHANNEL MODULATOR

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEES FOR THIS PAPER TO DEPOSIT

ACCOUNT NO. 23-0975

## PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents, Washington, DC 20231

Sir:

Attached hereto is a check in the amount of \$921.00 to cover Patent Office fees relating to filing the following attached papers:

Petition for Extension of Time ......\$200.00

Request For Suspension Of Action ••••• \$<u>130.00</u>

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

11/23/2001 HGEBREN1 00000013 09155076

370.00 OP 81.00 OP 140.00 DP Respectfully submitted,

Susan A. GREENEIELD et al.

Registration No. 40,949 Attorney for Applicants

LC/gtn

WENDEROTH, LIND & PONACK, L.L.P.

2033 K St., N.W., Suite 800

Washington, D.C. 20006-1021

Telephone (202) 721-8200

November 21, 2001

[Check No. 4761

Revised PTO/SB/29 (02/01)

MOV 2 1 2001

# CONTINUES NEED SECULATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing

(Only for Continuation or Divisional applications under 37 CFR 1.53(d)

CHECK BOX, if applicable

] DUPLICATE

Address to: TRADE

Assistant Commissioner for Patents Box CPA Washington, DC 20231

Attorney Docket No.	01727/N.80406 US/JCI/cl
First Named Inventor	Susan A. GREENFIELD et al.
Express Mail Label No.	
Total Pages	

This is a request for a [X] continuation or [] divisional application under 37 CFR 1.53(d) (continued prosecution application (CPA)) of prior application number 09/155,076, filed on October 23, 1998, entitled PEPTIDE FROM SOLUBLE FORM OF ACETYLCHOLINESTERASE, ACTIVE AS A CALCIUM CHANNEL MODULATOR.

#### NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

**EXPRESS ABANDONMENT OF PRIOR APPLICATION**: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 USC 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning the other application or applications in the file jacket.

35 USC 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 USC 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

- 1. [] Enter the unentered amendment previously filed on under 37 CFR 1.116 in the prior nonprovisional application.
- 2. [] A preliminary amendment is enclosed.

3. [] This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4). a.[] DELETE the following inventor(s) named in the prior nonprovisional application:

370.00 0 81.00 0 140.00 0

00000013 09155076

- b.[] The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
- 4. [] A new power of attorney or authorization of agent (PTO/SB/81) is enclosed MMISSIONER IS AUTHORIZE
- 5. [] Information Disclosure Statement (IDS) is enclosed:
   a.[] PTO-1449
   b.[] Copies of IDS Citations

TO CHARGE ANY DEFICIENCY IN THE FEES FOR THIS PAPER TO DEPOSITE ACCOUNT NO. 23-0975

FC: 331 FC: 303

Revised	PTO/SB/29	(01/01

CLAIMS	(1) FOR	(2) NUMBER FII	LED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	29 - 20	=	9	9 x \$18 =	\$162.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	1 - 3	=		0 x \$84 =	\$0.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))				+ \$280 =	\$280.00
					BASIC FEE (37 CFR 1.18(a))	\$740.00
	Total of above Calculations =					\$1,182.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28):					\$591.00
					TOTAL =	\$591.00

- 6. [X] Small entity status:
  - a.[X] Small Entity Statement is hereby asserted.
  - b.[] Is no longer claimed.
- 7. [X] The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 23-0975
  - a.[X] Fees required under 37 CFR 1.16.
  - b.[X] Fees required under 37 CFR 1.17.
  - c.[] Fees required under 37 CFR 1.18.
- 8. [X] A check in the amount of \$921.00 is enclosed.
- 9. [X] Applicant requests suspension of action under 37 CFR 1.103(b) for a period of three months (not to exceed 3 months) and the fee under 37 CFR 1.17(i) is enclosed.
- 10. [X] Return Receipt Postcard.
- 11. [X] Other: Preliminary Remarks and a Petition for a two month Extension of Time are attached herewith.

NOTE: The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.

#### 10. NEW CORRESPONDENCE ADDRESS

(Insert Customer No. or Attach bar code label here)

[X] Customer Number or Bar Code Label

or [ ] New correspondence address below

12. CORRESPONDENCE ADDRESS

000513

PATENT TRADEMARK OFFICE

By:

Registration No. 40,949

WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250

November 21, 2001



## IE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

ATTN: BOX CPA

Susan A. GREENFIELD et al.

Docket No. 01727/N.80406 US/JCI/cl

Serial No. 09/155,076

Group Art Unit 1647

Filed October 23, 1998

Examiner S. Turner

PEPTIDE FROM SOLUBLE FORM OF ACETYLCHOLINESTERASE, ACTIVE AS A CALCIUM CHANNEL MODULATOR

THE COME.
TO CHARGE

FEES FOR Trace -- I TO DEPOSIT.

**ACCOUNT NO. 23-0975** 

### **PRELIMINARY REMARKS**

Assistant Commissioner for Patents, Washington, D.C. 20231

Sir:

Applicants intend to file a preliminary paper in the new application responding to the grounds of rejection in the last Official Action.

The Examiner is kindly requested to postpone the issuance of a first Official Action in the new application while Applicants prepare this preliminary paper.

It would be very helpful to the Applicants if the Examiner would provide the Applicants' undersigned representative with an indication of the Examiner's deadline for issuing a first Official Action, if the preliminary paper has not been filed by the time the Examiner takes up the application for examination.

Respectfully submitted,

Susan A. GREENFIELD et al.

By:\_\_

Lee Cheng

Registration No. 40,949 Attorney for Applicants

LC/gtn Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 November 21, 2001